Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Sep 10, 2012 2:19pm
275 Views
Post# 20343299

RE: RE: RE: RE: RE: RE: Shakeup.

RE: RE: RE: RE: RE: RE: Shakeup.

RH is almost 60 years old. While he is certainly not a "stop gap" CEO, I don't think he will want to run HEM for more than a few years at most. Put yourself in his shoes. You have all your net worth in the form of HEM shares and you are in the later stages of your professional career. What would you do? IMO, RH will want to do anything and everything that will lift the share price (strategic initatives, cost rationalization, product focus, licensing etc etc). Once that's done, look for a buyer and sell the business. It's the logical conclusion and one that allows RH et. al to get the most for their shares. That doesn't mean a sale is imminent, but the probability of one occuring as the ultimate exit strategy for shareholders has increased considerably. 

Bullboard Posts